4 completed, 3 recruiting, 2 active not recruiting, 2 unknown. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Recruiting 3, Active not recruiting 2, Unknown 2, Not yet recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Prostate Cancer Recurrent: new trials by email Literature Review of Prostate Cancer Recurrent trials Research Report on Prostate Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | Shehzad Basaria, M.D. | 60 | 2026-01-14 | 2026-08-17 |
| PSMA-RLT in Biochemically Recurrent PCa [177Lu]Lu-PSMA I&T - Prostate Cancer Recurrent | Phase 2 | Recruiting | Medical University of Vienna | 20 | 2024-01-15 | 2024-02-13 |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Completed | MacroGenics | 154 | 2023-09-28 | 2026-05-22 |
| COAST Therapy in Advanced Solid Tumors and Prostate Cancer Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir - Prostate Cancer Recurrent, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 76 | 2022-03-03 | 2026-05-13 |
| MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer MBM-02 - Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer | Phase 2 | Unknown | Matrix Biomed, Inc. | 55 | 2021-05-30 | 2021-05-06 |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer Darolutamide, metastasis-directed treatment - Prostate Cancer, Prostate Cancer Recurrent | Phase 2 | Unknown | University Hospital, Ghent | 124 | 2021-02-12 | 2024-02-28 |
| Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer Hydroxychloroquine Sulfate 200Mg Tab - Prostate Cancer Recurrent | Phase 2 | Completed | Patrick Hensley | 20 | 2019-12-03 | 2025-04-11 |
| Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer RV001V, Placebo - Prostate Cancer Recurrent | Phase 2 | Active not recruiting | RhoVac APS | 180 | 2019-11-19 | 2021-09-28 |
| Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Ga-68 P16-093 PET/CT scan - Prostate Cancer Recurrent, Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Five Eleven Pharma, Inc. | 60 | 2018-05-10 | 2022-05-02 |
| Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence 68Ga-PSMA - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Completed | University of Michigan | 1435 | 2018-02-09 | 2023-11-03 |
| Metformin Prostate Cancer Adjuvant Trial Metformin Hydrochloride Extended Release 750mg - Prostate Cancer, Prostate Cancer Recurrent | Phase 2 | Completed | NYU Langone Health | 59 | 2014-06-01 | 2022-10-18 |
Prostatic Neoplasms (8) · Adenocarcinoma (1) · Hot Flashes (1) · Multiple Endocrine Neoplasia Type 1 (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms, Castration-Resistant (1)
Genital Diseases (9) · Genital Diseases, Male (9) · Genital Neoplasms, Male (9) · Male Urogenital Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Prostatic Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Pathological Conditions, Signs and Symptoms (2) · Carcinoma (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1)
Hydroxychloroquine (2) · Metformin (2) · 68 Ga-P16-093 (1) · Dasatinib (1) · Docetaxel (1) · Nelfinavir (1) · Prednisone (1) · Sirolimus (1) · TEMPOL-H (1) · bicalutamide (1) · darolutamide (1) · gallium 68 PSMA-11 (1) · tempol (1)
Five Eleven Pharma, Inc. (1) · MacroGenics (1) · Matrix Biomed, Inc. (1) · Medical University of South Carolina (1) · Medical University of Vienna (1) · NYU Langone Health (1) · Patrick Hensley (1) · RhoVac APS (1) · Shehzad Basaria, M.D. (1) · University Hospital, Ghent (1) · University of Michigan (1) · Washington University School of Medicine (1)
United States (10) · Belgium (3) · United Kingdom (2) · Australia (1) · Austria (1) · Bulgaria (1) · Denmark (1) · Finland (1) · France (1) · Georgia (1) · Germany (1) · Poland (1) · Puerto Rico (1) · Spain (1) · Sweden (1)
Aaron E Katz, MD (1) · Klaus Brasso, MD (1) · Mark Green, PhD (1) · Morand R Piert, M.D. (1) · Patrick J Hensley, MD (1) · Peng Wang, MD (1) · Pepi Pencheva, M.D. (1) · Piet Ost, MD, PhD (1) · Shehzad S Basaria, MD (1) · Vikas Prasad, MD, PhD (1)